EirGenix Secures $152 M Licensing Deal for EG1206A Breast‑Cancer Biosimilar from Sandoz
EirGenix Inc. (TPE: 6589) announced a second, worldwide exclusive licensing agreement with Sandoz AG (SWX:...
EirGenix
EirGenix’s Trastuzumab Biosimilar Receives European Commission Marketing Approval
EirGenix Inc., (6589.TT) a Taiwan-based pharmaceutical company, has announced that it has received marketing approval...